Outcomes Measures: Plasma total and incremental triglyceride, VLDL-apoB-100 and apoB-48 0-10 h area-under-the-curves (AUCs).
INTRODUCTION
Familial hypercholesterolemia (FH) is the commonest monogenic cause of hypercholesterolemia and premature atherosclerotic cardiovascular disease (ASCVD), with a population frequency of at least 1 in 500 (1) . FH results principally from mutations in the low-density lipoprotein (LDL) receptors that impair LDL catabolism and markedly increase plasma LDL-cholesterol concentrations (2) . While FH markedly increases the onset of premature coronary heart disease (CHD), risk can be variable and this may relate to other cardiovascular risk factors or to hidden mechanisms, including postprandial lipemia (3) (4) (5) (6) . However, despite treatment of statin, with or without ezetimibe, a significant proportion of FH patients remain at increased residual risk of
ASCVD (3).
Postprandial hypertriglyceridemia reflects prolonged accumulation of triglyceride-rich lipoproteins (TRLs), including very-low-density lipoprotein (VLDL)-apolipoprotein (apo) B-100 and apoB-48-containing chylomicrons and their remnants in the circulation (7). These lipoproteins are atherogenic, contributing to inflammation, oxidative stress, endothelial dysfunction and foam cell formation (3, 7, 8) . Recent evidence from experimental and human studies suggests that deficiency in LDL receptor function in FH may disturb TRL metabolism by delaying remnant clearance (9, 10). Furthermore, there is evidence showing that apoB-48 concentrations are elevated in FH due to an increased production rate (11). We have recently demonstrated that elevated fasting triglyceride concentration is a significant predictor of CHD in FH (12). Patients with FH may accordingly have impaired triglyceride response to a fatty meal irrespective of the plasma triglyceride concentrations (4) (5) (6) . This may contribute to increased CHD risk in FH patients.
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Fish oils are a rich source of long-chain ω-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). There is some evidence that fish oil supplementation protects against cardiovascular disease and this may be partly mediated by improvement in hypertriglyceridemia (13, 14) . However, data from several meta-analyses suggest that fish oil supplementation does not lower risk of major CVD events (15) (16) (17) . It should be noted, however, most of these studies used low doses of fish oil supplementation (<2 g/day). We have previously reported that ω-3 fatty acid ethyl ester (ω-3 FAEE) supplementation (4 g/day) lowers fasting and postprandial triglyceride concentrations in obese subjects (18) . To date, no study has examined the effect of ω-3 FAEE supplementation on postprandial TRL response in FH patients receiving standard treatment for lowering LDL-cholesterol.
In the present study, we investigated the responses of triglyceride and apoB-48 concentrations following ingestion of an oral fat load. We hypothesized that ω-3 FAEE would reduce postprandial responses for plasma triglycerides and apoB-48 in FH patients who were on statin and/or ezetimibe treatment.
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METHODS
Subjects
Twenty-two patients (11 men and 11 women) with FH aged 18-70 years [body mass index (BMI) <40 kg/m2] were recruited from the Lipid Disorders Clinic at Royal Perth Hospital. Diagnosis of FH was defined by the Dutch Lipid Clinic Network criteria (DLNC) score >8 (definite FH) and/or the presence of a pathogenic mutation in the LDLR gene (19) . However, one subject withdrew consent before completing the first intervention period, and another was withdrawn because of an adverse event related to atrial fibrillation during the isotopic infusion that resolved spontaneously. Homozygous and compound/double heterozygous FH, and subjects with APOB (i.e. familial defective apoB-100 or familial hypobetalipoproteinemia) and PCSK9 mutations were excluded. None of the subjects were APOE ɛ2 homozygotes, nor had proteinuria, creatininemia (>120 µmol/L), hypothyroidism, or abnormal liver enzymes (alanine aminotransferase >120 U/L for men and >90 U/L for women). None reported a cardiovascular event within six months prior to the study, or were taking ω-3 FAEE supplementation (within the last six months); or antidiabetic medication. The study was approved by the Human Research Ethics Committee of the Royal Perth Hospital, and written informed consent was obtained from all subjects.
Clinical Protocol
This study was an open-label, randomized, cross-over intervention trial (Figure 1 ). The study protocol included infusion of a stable isotope to assess TRL kinetics, which will be reported separately. All eligible patients were on statins (or statin plus ezetimibe) at recruitment and throughout the duration of the study. All patients entered a 4-week run-in diet stabilizing period, at the end of which they were randomized to into one of the two groups, no treatment or a 8-week treatment period of 4 g/day ω-3 FAEE supplementation (Omacor® 46% EPA and 38% DHA in ethyl ester form, Abbott Products Pty Ltd) with a 8-week washout between each intervention period. Compliance with ω-3 FAEE supplementation was confirmed by capsule count at the end of ω-3 FAEE intervention. Three-day food, alcohol and exercise diaries were given to the participants to complete at the end of each treatment period. Diaries were assessed for energy and major nutrients completed during the lead-in period (week 4) and at the end of each treatment period (week 12 and 28) using FoodWorks 7 Pro (Xyris, Queensland Australia). Physical activity was also assessed by a seven day recall questionnaire at the end of each treatment period (20) .
All dietary assessments and recommendations were conducted by a registered dietitian. All subjects were reviewed fortnightly and requested to maintain their dietary intake and level of physical activity constant.
Comparison with non-FH controls
For comparison purpose, 10 healthy non-FH subjects (5 men and 5 women, age 59 ± 7 years, weight 83 ± 12 kg, BMI 28.9 ± 5.7 kg/m 2 , systolic blood pressure 126 ± 12 mmHg, diastolic blood pressure 75 ± 7 mmHg, plasma triglycerides 1.20 ± 0.56 mmol/L and total cholesterol 5.29 ± 0.87 mmol/L on no drug treatment) were also recruited from the community in which the fat load test was performed once.
Postprandial oral fat-load test
All subjects were admitted to the metabolic ward in the morning after a 14-h fast. They were studied in a semi-recumbent position and allowed to drink only water after the test-meal. Arterial blood pressure was recorded after 3 min in the supine position using a Dinamap1846 SX/P monitor (Critikon Inc, Tampa, FL, USA). Following a baseline fasting blood sample, a liquid formulated high fat test meal was the consumed within 2 min (a total of 4800kJ, 130 g fat, 17 g protein and 21 g carbohydrate), following with blood samples were obtained after 30, 40 min, and 1, 2, 3, 4, 6, 8 and 10 h (18) . Briefly, the test meal was a milkshake consisting of 100 mL of full cream milk, 150 mL of pure cream, 70 mL of corn oil, 90 g of whole egg (approximately 2 large eggs) and 10 g of sugar. The meal provided 470mg cholesterol and 120g fat (polyunsaturated fat 27%, monounsaturated fat 28% and saturated fat 40%). Subjects were then given a snack and allowed to go home. All the procedures were repeated after 8-week intervention period.
Biochemical measurements
Fasting whole venous blood samples collected in EDTA were immediately centrifuged at 1500 x g for 15 min at 4°C. Plasma was collected and stored at -80°C for analysis. Plasma lipid and glucose concentrations were measured using enzymatic methods (Hitachi 917 Biochemical Analyser, Roche Diagnostics Australia Pty Limited, Castle Hill, NSW, Australia). LDL cholesterol was estimated by the Friedewald calculation. Lipoprotein(a) was measured with a turbidimetric method using immunoglobulin G anti-human Lp(a) (Quantia Lp(a) assay and standard). Fasting insulin was measured using chemiluminescent immunometric assay (Abbott Diagnostics, North Ryde, NSW, Australia), and insulin resistance was estimated using homeostasis model assessment (HOMA) score (21) . Plasma apoB-48 levels were measured by enzyme immunoassay kit with an intra-assay CV of <6% (Fujirebio, Tokyo, Japan). VLDL fraction was isolated from 3.5 mL plasma by ultracentrifugation (Optima XL-100K, Beckman Coulter, Australia) at d=1.006 g/mL (40,000 rpm, 16 h, 4°C). VLDL-apoB-100 was measured using ELISA kit (Mabtech, Nacka, Sweden). This kit is specific for apoB-100 and does not recognize apoB-48.
Postprandial metabolism was quantified by calculating the area-and incremental under-the-curve (AUC) and iAUC, respectively, for plasma triglyceride, VLDL-apoB-100 and apoB-48 (0-10 h) using the trapezium rule. The iAUC was estimated as the difference between the area defined below the baseline concentration and the area under the plasma curve between 0 and 10 h.
Statistical Analyses
Data are reported as mean ± SEM unless specified. Skewed variables were log-transformed.
Statistical significance was defined at the 5% level using a two-tailed test. Our sample size for this study was based on a previous study that ω-3 FAEE supplementation decreased the AUCs for triglyceride and apoB-48 by 30% (18) . Groups were compared using independent t-tests using the SPSS 21 (SPSS, Chicago, IL) software. Carry-over effects of the crossover design were estimated based on the Grizzle's model using general linear modeling (PROC GLM, SAS 9.2 SAS Institute, Cary, North Carolina, USA). If the carryover effect was not statistically significant, then the data from the two periods was combined and analyzed using paired t-test to estimate the treatment effect of ω-3 FAEE supplementation in our FH patients.
RESULTS
Baseline characteristics
A total of twenty patients (10 men and 10 women) completed the study. Of these subjects, seventeen patients were genetically diagnosed with FH (i.e., pathogenic mutations in the LDLR gene) and the other three had a DLNC score >8 (definite phenotypic FH). The LDLR mutations were classified as follows: Class 1 (n=3), Class 2 (n=3), Class 4 (n=2), Class 5 (n=4) and intron splice site (n=5). Of the 20 FH patients, 13 of the FH patients men were APOE ɛ3ɛ3 homozygotes, 2 were APOE ɛ2ɛ3 heterozygotes, 2 were APOE ɛ3ɛ4 heterozygotes, 2 were APOE ɛ2ɛ4 heterozygote and 1 were APOE ɛ4ɛ4 homozygotes. On average, they were middle-aged (53.3 ± 3.0 years), non-obese (BMI 27.0 ± 6.3 kg/m 2 ), normotensive and normolipidemic (Table 1) . Nine patients were on rosuvastatin (12.5-40 mg/day), eight on atorvastatin (40-80 mg/day) and three on simvastatin (80 mg/day). Of these, thirteen patients were also on ezetimibe (10 mg/day). Nine patients were on aspirin, three on anti-hypertension medication and four had a history of CAD event. Baseline (lead-in) average daily energy and nutrient intake of the 20 FH studied was 7270 ± 1720 kJ, 33 ± 5% energy from fat, 44 ± 8% energy from carbohydrates, 20 ± 3% energy from protein and 3 ± 2% energy from alcohol; cholesterol intake 278 ± 122 mg. The percent contribution of total fat from dietary polyunsaturated, monounsaturated and saturated fat was 23 ± 9%, 38 ± 8% and 39 ± 8%, respectively. Table 1 shows the effects of ω-3 FAEE supplementation on clinical and biochemical characteristics in the 20 FH patients. Body weight, waist circumference and BMI did not alter significantly during the intervention (P>0.05 in all). ω3-FAEE supplementation significantly (P<0.05 in all) lowered systolic blood pressure (-6%) and diastolic blood pressure (-6%), plasma triglycerides (-20%), apoB (-8%), VLDL-apoB-100 (-26%) and plasma apoB-48 (-36%) concentration. ω-3 FAEE supplementation tended to lower total cholesterol and non-HDL-9 cholesterol concentrations, but the difference was not statistically significant (P<0.1 for both).
Body weight, blood pressure and biochemical characteristics
LDL-cholesterol and HDL-cholesterol concentrations were not significantly altered with ω-3 FAEE supplementation, nor were glucose, insulin concentrations and HOMA score. No significant changes in dietary and physical activity levels were reported during the study (data not shown).
Capsule counts confirmed that compliance with randomization to ω-3 FAEE intervention was >95%. There were no side effects reported with ω-3 FAEE supplementation. 
Postprandial lipid responses
Case vs Controls
ω-3 FAEE intervention
The postprandial responses for plasma triglycerides, VLDL-apoB-100
and apoB-48 to the fat load are shown in Figure 2 . As seen in Figure 3 , ω-3 FAEE supplementation significantly reduced postprandial triglyceride and VLDL-apoB-100 total AUCs P<0.05). Postprandial apoB-48 total AUC (0-10 h) was also significantly reduced with ω-3 FAEE supplementation (-30%, P<0.02). ω-3 FAEE supplementation lowered postprandial apoB-48 incremental AUC (-25%), but this failed to reach statistical significance (P=0.09). The effects of ω-3 FAEE supplementation on postprandial triglyceride and VLDL-apoB-100 total and incremental AUCs, as well as postprandial apoB-48 total AUCs were comparable between FH men and women and were not dependent on the presence nor class of LDLR mutations nor APOE genotype (data not shown).
DISCUSSION
The major finding of this study was that FH patients with normal fasting plasma triglyceride concentrations had impaired postprandial triglyceride, VLDL-apoB-100 and apoB-48 responses to a fat load and these abnormalities were partially corrected by ω-3 FAEE supplementation. This was reflected by decreasing both fasting concentrations and total postprandial AUCs of triglyceride, VLDL-apoB-100 and apoB-48, against a background of cholesterol-lowering therapy (statin with and without ezetimibe). apoB-48 AUC in subjects with hypertriglyceridemia (24) . We have recently reported that the addition of 16-week ω-3 FAEEs (4 g/day) to a moderate weight loss diet significantly reduced fasting and total postprandial AUCs of triglyceride and apoB-48 in obese subjects (18) . The aforementioned discrepant findings might be explained by differences in subject characteristics, as well as the duration (4 to 16 weeks) and dose and composition of the fish oils employed (1.7 g to 5.2 g/day). We extend these studies by employing high dose ω-3 FAEE supplementation (4 g/day) and examining FH patients against a background of cholesterol-lowering treatment (i.e.
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statin with or without ezetimibe). 
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